MEDDAY'S MD1003 STUDY FAILS TO REACH PRIMARY ENDPOINT

Biotin is an emerging therapy for the treatment of secondary progressive MS.

MEDDAY'S MD1003 STUDY FAILS TO REACH PRIMARY ENDPOINT

Postby seeva » Tue Dec 22, 2015 3:29 pm

User avatar
seeva
Family Elder
 
Posts: 451
Joined: Sun Jan 20, 2008 4:00 pm
Location: SYDNEY

Advertisement

Re: MEDDAY'S MD1003 STUDY FAILS TO REACH PRIMARY ENDPOINT

Postby CureOrBust » Tue Dec 22, 2015 4:03 pm

You need to register to read the actual report. Checking Medways website, I found this page
http://www.medday-pharma.com/news-and-events/medday-provides-update-on-ms-on-study-of-md-1003/
with this quote
MedDay wrote:Patients who received MD1003 tended to improve slightly more than patients who received the placebo (3 letters mean improvement in the MD1003 arm versus 1.8 letters in the placebo arm) however the difference did not reach statistical significance and overall the study did not meet its primary endpoint.
User avatar
CureOrBust
Family Elder
 
Posts: 3341
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Re: MEDDAY'S MD1003 STUDY FAILS TO REACH PRIMARY ENDPOINT

Postby DrGeoff » Tue Dec 22, 2015 4:23 pm

And do please note that this study was directed at Optical Neuritis in progressive and relapsing forms.
And, like COB points out, the MD1003 worked - but not quite enough to meet statistical significance.
Also, consider what this tells us about MedDay - they are not attempting to massage the figures to make their product look better than it is. I have known researchers in the past who would wait until the data was in and then "design" the study to fit the data.
Geoff
DrGeoff
Family Elder
 
Posts: 194
Joined: Mon Aug 05, 2013 3:44 am

Re: MEDDAY'S MD1003 STUDY FAILS TO REACH PRIMARY ENDPOINT

Postby David1949 » Sat Dec 26, 2015 9:19 am

Can we conclude then that MD1003 is another dud?
And what happened to the first study that showed positive results?
David1949
Family Elder
 
Posts: 830
Joined: Mon Aug 23, 2010 3:00 pm

Re: MEDDAY'S MD1003 STUDY FAILS TO REACH PRIMARY ENDPOINT

Postby DrGeoff » Sat Dec 26, 2015 2:43 pm

David1949 wrote:Can we conclude then that MD1003 is another dud?
And what happened to the first study that showed positive results?

If you conclude that, David, then you have failed to read the other posts in this thread.

The latest MD1003 trial was directed specifically at Trigeminal Neuralgia.
Far from being a dud, it worked. It did not work well enough to reach the relevant value for statistical significance for the number of participants involved in the trial. As a general guide, the lower the number of participants, the larger the required value of p

As for the first study, the results have been presented at several conferences, and have generated a considerable amount of interest.
They have also led to the creation of several Facebook groups, at least one blog, have led to threads on several of the MS forums world wide, and you can find quite a lot about it here on TiMS.
The results of that study did meet statistical significance.

Geoff
DrGeoff
Family Elder
 
Posts: 194
Joined: Mon Aug 05, 2013 3:44 am


Return to Biotin (Qizenday, Cerenday, MD1003)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service


cron